Christopher Orton

Professor of Pharmaceutical Compounding at University of Utah College of Pharmacy
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Salt Lake City Metropolitan Area
Languages
  • Portuguese -

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Credentials

  • USP 797
    University of Utah College of Pharmacy
    Sep, 2015
    - Oct, 2024
  • Immunization Certification
    American Pharmacists Association
    Sep, 2014
    - Oct, 2024
  • Pharmacist
    Utah Division of Occupational and Professional Licensing
    Sep, 2017
    - Oct, 2024
  • Basic Life Support
    International CPR Institute
    Jul, 2015
    - Oct, 2024
  • Pharmacy Intern
    Utah Division of Occupational and Professional Licensing
    Jul, 2013
    - Oct, 2024

Experience

    • United States
    • Higher Education
    • 1 - 100 Employee
    • Professor of Pharmaceutical Compounding
      • Aug 2021 - Present

    • Pharmacist, Owner
      • Jun 2018 - Present

    • United States
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Staff Pharmacist
      • May 2017 - May 2018

    • United States
    • Retail
    • 700 & Above Employee
    • Pharmacy Intern
      • Oct 2013 - Apr 2017

      Active role in the input, processing/billing, filling, verification, and patient counseling of all prescriptions. Active role in the input, processing/billing, filling, verification, and patient counseling of all prescriptions.

    • Staff Scientist/Principal Investigator - Department of Drug Metabolism
      • Jul 2009 - Jul 2013

      Performed metabolite identification and structure characterization using state of the art, high resolution, liquid chromatography mass spectrometry (LC-MS). Good laboratory practice (GLP) based metabolite profiling of test compounds utilizing high-performance liquid chromatography (HPLC) and radio-chromatography. Provided quantitative LC-MS support for pharmacokinetic/toxicokinetic (PK/TK) studies. Implementing and troubleshooting LC-MS instrumentation and method development. Performed metabolite identification and structure characterization using state of the art, high resolution, liquid chromatography mass spectrometry (LC-MS). Good laboratory practice (GLP) based metabolite profiling of test compounds utilizing high-performance liquid chromatography (HPLC) and radio-chromatography. Provided quantitative LC-MS support for pharmacokinetic/toxicokinetic (PK/TK) studies. Implementing and troubleshooting LC-MS instrumentation and method development.

    • United States
    • Hospitals and Health Care
    • 700 & Above Employee
    • Postdoctoral Research Fellow - Departments of Pharmacology & Toxicology and Pediatrics
      • Sep 2006 - Jul 2009

      Involved in projects comparing metabolism of inhaled glucocorticoids by cytochrome P450 3A enzymes in the lung (metabolite ID, structure elucidation (LC/MS), kinetic parameters (VMAX and KM)). Regulation of P450 3A enzymes in airway cells by inhaled glucocorticoids (qRT-PCR) and subsequent effects on glucocorticoid metabolism and developmental expression of P450 3A enzymes measuring P450 3A expression in airways of pediatric patients Performed preliminary work on a genotyping study (genotyping pediatric asthmatics for P450 3A polymorphisms). Show less

    • United States
    • Higher Education
    • 700 & Above Employee
    • Research Assistant - Department of Biochemistry
      • Jul 2003 - Aug 2006

      Finding correlations between protein adduction with activation of specific cell signaling events (survival, death, apoptosis, etc.), more specifically activation of c-Jun N-terminal kinase, a member of the mitogen activated cell kinase (MAPK) family of enzymes and activation of apoptotic pathways. Also making chemical comparisons of extents of protein adduction in different cell types by different adducting agents (Michael vs. SN2 mechanism, etc.) Finding correlations between protein adduction with activation of specific cell signaling events (survival, death, apoptosis, etc.), more specifically activation of c-Jun N-terminal kinase, a member of the mitogen activated cell kinase (MAPK) family of enzymes and activation of apoptotic pathways. Also making chemical comparisons of extents of protein adduction in different cell types by different adducting agents (Michael vs. SN2 mechanism, etc.)

    • United States
    • Higher Education
    • 700 & Above Employee
    • Graduate Student Researcher - Department of Pharmacology & Toxicology
      • Jul 2001 - Jul 2003

      Identifying protein adducts on glutathione S-transferase (GST) P1-1 using model Michael and SN2 mechanism based compounds by LC-MS techniques. Developed methodology to simultaneously compare multiple adduction sites on the same protein using N-terminal peptide labeling with phenyl isocyanate and quantitative LC-MS to calculate rate constant (k) for each site with different modifying chemicals. Identifying protein adducts on glutathione S-transferase (GST) P1-1 using model Michael and SN2 mechanism based compounds by LC-MS techniques. Developed methodology to simultaneously compare multiple adduction sites on the same protein using N-terminal peptide labeling with phenyl isocyanate and quantitative LC-MS to calculate rate constant (k) for each site with different modifying chemicals.

Education

  • University of Utah
    Doctor of Pharmacy (PharmD)
    2013 - 2017
  • University of Arizona
    Doctor of Philosophy (Ph.D.), Pharmacology and Toxicology
    2001 - 2006
  • Southern Utah University
    Bachelor of Arts (B.A.), Biochemistry
    1997 - 2000

Community

You need to have a working account to view this content. Click here to join now